Complement 3b deposition on Rituximab opsonized

Brought to you by:

First Name *

Last Name *

Email *

Phone Number *

Company *

Company Address *

City *

Country *

State/Province *

Postal Code *

Job Title *

Company Size

Industry *

Get the White Paper

FREE White Paper

Complement 3b Deposition on Rituximab Opsonized

Sponsored by EMD Millipore

The ImageStream® imaging flow cytometry platform was used to study the mechanism of action of Rituximab (RTX). RTX is a therapeutic monoclonal antibody directed against CD20 for the treatment of Non-Hodgkin’s lymphoma. In this experiment, B cells were opsonized with RTX (labeled with AlexaFluor® 488 (AF488)) and analyzed for C3b deposition after incubation in normal human serum as a source of complement. Using the ImageStream® platform we were able to quantify the degree of co-localization between Rituximab and C3b using the Bright Detail Similarity algorithm available in the IDEAS® software.

Privacy Policy

This data may be used by the sponsor to provide you with information within the scope of this white paper. Any information you submit by this form will only be used for the purposes indicated. You can trust Advantage Business Media not to rent, sell, exchange, or give your information to any third party without permission.